39
Participants
Start Date
December 17, 2024
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2027
Ivonescimab Combined With TROP2 ADC
Ivonescimab: 20 mg/kg, ivggt, day 1, every 3 weeks; Sacituzumab govitecan: 10 mg/kg, ivggt, day 1 and day 8, every 3 weeks;
RECRUITING
Fudan University Shanghai Cancer center, Shanghai
Fudan University
OTHER